In many instances of cutaneous sarcoidosis, clinicians are moving away from conventional immunosuppressants and toward molecularly targeted therapies, such as TNF inhibitors, and in some cases JAK ...

CEO Matt Gline highlighted 2025 as a year of major milestones, focusing on validating the anti-FcRn franchise with upcoming MG and CIDP data and a central registrational readout for dermatomyositis, ...

Please provide your email address to receive an email when new articles are posted on . SAN DIEGO — Rheumatologists may be the best clinicians to manage the challenges presented by sarcoidosis, which ...